» Articles » PMID: 32580896

Pediatric Lung Transplantation: Dynamics of the Microbiome and Bronchiolitis Obliterans in Cystic Fibrosis

Abstract

Background: Compositional changes in the microbiome are associated with the development of bronchiolitis obliterans (BO) after lung transplantation (LTx) in adults with cystic fibrosis (CF). The association between the lower airway bacterial community and BO after LTx in children with CF remains largely unexplored and is possibly influenced by frequent antibiotic therapy. The objectives of this study were to examine the relationship between bacterial community dynamics and the development of BO and analyze antibiotic resistance trends in children after LTx for CF.

Methods: For 3 years from the time of transplant, 12 LTx recipients were followed longitudinally, with 5 subjects developing BO during the study period. A total of 82 longitudinal bronchoalveolar lavage samples were collected during standard of care bronchoscopies. Metagenomic shotgun sequencing was performed on the extracted microbial DNA from bronchoalveolar lavage specimens. Taxonomic profiling was constructed using WEVOTE pipeline. The longitudinal association between development of BO and temporal changes in bacterial diversity and abundance were evaluated with MetaLonDA. The analysis of antibiotic resistance genes was performed with the ARGs-OAP v2.0 pipeline.

Results: All recipients demonstrated a Proteobacteria-predominant lower airways community. Temporal reduction in bacterial diversity was significantly associated with the development of BO and associated with neutrophilia and antibiotic therapy. Conversely, an increasing abundance of the phylum Actinobacteria and the orders Neisseriales and Pseudonocardiales in the lower airways was significantly associated with resilience to BO. A more diverse bacterial community was related to a higher expression of multidrug resistance genes and increased proteobacterial abundance.

Conclusions: Decreased diversity within bacterial communities may suggest a contribution to pediatric lung allograft rejection in CF.

Citing Articles

Lung microbiome: new insights into the pathogenesis of respiratory diseases.

Li R, Li J, Zhou X Signal Transduct Target Ther. 2024; 9(1):19.

PMID: 38228603 PMC: 10791971. DOI: 10.1038/s41392-023-01722-y.


Mapping bacterial diversity and metabolic functionality of the human respiratory tract microbiome.

Mancabelli L, Milani C, Fontana F, Lugli G, Tarracchini C, Turroni F J Oral Microbiol. 2022; 14(1):2051336.

PMID: 35309410 PMC: 8933033. DOI: 10.1080/20002297.2022.2051336.


Informatic analysis of the pulmonary microecology in non-cystic fibrosis bronchiectasis at three different stages.

Wang Y, Chen Y, Wu C, Yang X Open Life Sci. 2022; 17(1):107-120.

PMID: 35291562 PMC: 8886608. DOI: 10.1515/biol-2022-0014.


The impact of gastrointestinal dysmotility on the aerodigestive microbiome of pediatric lung transplant recipients.

Lotstedt B, Boyer D, Visner G, Freiberger D, Lurie M, Kane M J Heart Lung Transplant. 2020; 40(3):210-219.

PMID: 33349521 PMC: 10329775. DOI: 10.1016/j.healun.2020.11.013.

References
1.
Ratner D, Mueller C . Immune responses in cystic fibrosis: are they intrinsically defective?. Am J Respir Cell Mol Biol. 2012; 46(6):715-22. DOI: 10.1165/rcmb.2011-0399RT. View

2.
Meyer K, Raghu G, Verleden G, Corris P, Aurora P, Wilson K . An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J. 2014; 44(6):1479-503. DOI: 10.1183/09031936.00107514. View

3.
Thabut G, Mal H . Outcomes after lung transplantation. J Thorac Dis. 2017; 9(8):2684-2691. PMC: 5594127. DOI: 10.21037/jtd.2017.07.85. View

4.
Elborn J . Cystic fibrosis. Lancet. 2016; 388(10059):2519-2531. DOI: 10.1016/S0140-6736(16)00576-6. View

5.
Burguete S, Maselli D, Fernandez J, Levine S . Lung transplant infection. Respirology. 2012; 18(1):22-38. PMC: 7192226. DOI: 10.1111/j.1440-1843.2012.02196.x. View